ResMed Inc. cash flow to debt ratio of 212.08% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

ResMed Inc.'s free cash flow has increased 29.18% from $1.29B last year to $1.66B, signaling increasing performance

ResMed Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

ResMed Inc.'s debt has decreased relative to shareholder equity from 0.14 last year to 0.13 today, signaling strengthened financials

ResMed Inc. has a net cash position, so leverage is healthy.

ResMed Inc.'s interest coverage ratio of 65.20 indicates that earnings with good margin can cover interest payments on company debt

ResMed Inc.'s profit margin has decreased (1.00%) in the last year from 27.22% to 26.94%, signaling decreasing performance

ResMed Inc.'s short-term assets of $4.32B exceed its short-term liabilities of $1.40B

ResMed Inc.'s return on assets of 16.99% is higher than the 5.00% threshold, indicating efficient asset utilization

ResMed Inc.'s return on equity of 23.88%, is higher than 15.00%, indicating good performance

ResMed Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

ResMed Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

ResMed Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

ResMed Inc. has a free cash flow yield of 5.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

ResMed Inc.'s yearly earnings has increased 8.75% since last year from $1.40B to $1.52B, signaling increasing performance

ResMed Inc.'s yearly revenue has increased 9.85% since last year from $5.15B to $5.65B, signaling increasing performance

ROIC 19.11% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

ResMed Inc.'s 3-year revenue CAGR of 10.21% is positive, indicating growing revenue over the past 3 years

ResMed Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

ResMed Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

ResMed Inc. is overvalued relative to its fair value price of 204.53 based on Discounted Cash Flow model

ResMed Inc. has an earnings yield of 4.78%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

ResMed Inc. is overvalued relative to its fair value price of 94.21 based on EBITDA multiple model

ResMed Inc. has an EV/EBITDA ratio of 14.57x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

ResMed Inc. is undervalued relative to its fair value price of 220.43 based on Earnings Fair Value model

ResMed Inc. has a PEG-ratio under 1 which is considered undervalued

ResMed Inc. has a price-to-book ratio of 4.84x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ResMed Inc. has a price-to-sales ratio of 5.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue